Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects

Journal of Clinical Pharmacology

Volumn 47, Issue 6, 2007, Pages 689-696

  Schentag, Jerome J ^a   Hill, George ^b   Chu, Tom ^b   Rayner, Craig R ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Caucasian; Japanese; Oseltamivir; Oseltamivir carboxylate; Pharmacokinetics

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR; PLACEBO;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG HYDROXYLATION; DRUG TOLERABILITY; ETHNIC DIFFERENCE; ETHNIC GROUP; ETHNICITY; FLATULENCE; HEADACHE; HUMAN; IC 50; INFLUENZA VIRUS A; INFLUENZA VIRUS B; JAPANESE; LOOSE FECES; MALE; NAUSEA; NEUTROPHIL COUNT; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; VIRUS ISOLATION;

ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; DOUBLE-BLIND METHOD; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; JAPAN; MALE; OSELTAMIVIR; PRODRUGS;

EID: 34249028187     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007299761     Document Type: Article

References (38)

1. Nicholson KG Human influenza. In: Nicholson KG, Webster RG, Hay AJ, eds. Textbook of Influenza. Oxford, UK: Blackwell Science ; 1998: 219-264.
2. Nicol KL Efficacy/clinical effectiveness of inactivated influenza virus vaccines in adults. In: Nicholson KG, Webster RG, Hay AJ, eds. Textbook of Influenza. Oxford, UK: Blackwell Science ; 1998: 358-372.
3. Stephenson I., Nicholson KG Influenza: vaccination and treatment. Eur Respir J. 2001 ; 17: 1282-1293.
4. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet. 2000 ; 355: 1845-1850.
5. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000 ; 283: 1016-1024.
6. Kaiser L., Wat C., Mills T., Mahoney P., Ward P., Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003 ; 163: 1667-1672.
7. Mitamura K., Sugaya N., Nirasawa M., et al. Effectiveness of oseltamivir treatment against influenza type A and type B infection in children [in Japanese]. Kansenshogaku Zasshi. 2002 ; 76: 946-952.
8. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001 ; 20: 127-133.
9. Welliver R., Monto AS, Carewicz O., et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001 ; 285: 748-754.
10. Hayden FG, Atmar RL, Schilling M., et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med. 1999 ; 341: 1336-1343.
11. Hayden FG, Belshe R., Villanueva C., et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis. 2004 ; 189: 440-449.
12. Peters PH Jr, Gravenstein S., Norwood P., et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc. 2001 ; 49: 1025-1031.
13. Lin JT, Yu XZ, Cui DJ, et al. A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population. Curr Med Res Opin. 2006 ; 22: 75-82.
14. Machado CM, Boas LS, Mendes AV, et al. Use of oseltamivir to control influenza complications after bone marrow transplantation. Bone Marrow Transplant. 2004 ; 34: 111-114.
15. Shijubo N., Yamada G., Takahashi M., Tokunoh T., Suzuki T., Abe S. Experience with oseltamivir in the control of nursing home influenza A outbreak. Intern Med. 2002 ; 41: 366-370.
16. Thakrar B., Dutkowski R., Froehlich E., et al. Oseltamivir is well tolerated by all patient groups [abstract]. Presented at: 4th European Congress of Chemotherapy and Infection ; May 4-7, 2002 ; Paris, France.
17. Dutkowski R., Thakrar B., Froehlich E., Suter P., Oo C., Ward P. Safety and pharmacology of oseltamivir in clinical use. Drug Saf. 2003 ; 26: 787-801.
18. Oo C., Barrett J., Hill G., et al. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children. Paediatr Drugs. 2001 ; 3: 229-236.
19. Oo C., Hill G., Dorr A., et al. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years. Eur J Clin Pharmacol. 2003 ; 59: 411-415.
20. Massarella JW, He GZ, Dorr A., Nieforth K., Ward P., Brown A. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers. J Clin Pharmacol. 2000 ; 40: 836-843.
21. He G., Massarella J., Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet. 1999 ; 37: 471-484.
22. Abe M., Smith J., Urae A., Barrett J., Kinoshita H., Rayner CR Pharmacokinetics of oseltamivir in young and very elderly Japanese subjects. Ann Pharmacol. 2006 ; 40: 1724-1730.
23. He G., Massarella J., Schulz R., et al. The effect of food on the pharmacokinetics of the novel oral neuraminidase inhibitor Ro 64-0796/GS4104 [abstract]. Presented at: Southeast Regional Meeting of the American Association of Pharmaceutical Scientists ; June 21, 1999 ; Durham, NC.
24. He G., Massarella J., Robson R., et al. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor Ro 64-0796/ GS4104 in subjects with renal impairment [abstract]. Presented at: 9th European Congress of Clinical Microbiology and Infectious Diseases ; March 21-25, 1999 ; Berlin, Germany.
25. Snell P., Dave N., Wilson K., et al. Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate. Br J Clin Pharmacol. 2005 ; 59: 598-601.
26. Kim K., Johnson JA, Derendorf H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol. 2004 ; 44: 1083-1105.
27. Hidetoshi T., Himori N., Ninomiya Y. Phase I clinical study of RO 64-0796 in healthy male volunteers. Data on file, Roche (report no. PDN99-04F, 1999 ).
28. Butcher RD, Cox G., Dorr A., et al. Multiple ascending oral dose study of the tolerability, safety and pharmacokinetics of the neuraminidase inhibitor RO 64-0796 in healthy volunteers. Data on file, Roche (report no. W-144070, 1998 ).
29. Mendel DB, Tai CY, Escarpe PA, et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother. 1998 ; 42: 640-646.
30. Marsh S., Xiao M., Yu J., et al. Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics. 2004 ; 84: 661-668.
31. Charasson V., Bellott R., Meynard D., Longy M., Gorry P., Robert J. Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clin Pharmacol Ther. 2004 ; 76: 528-535.
32. Wu MH, Chen P., Wu X., et al. Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene. Pharmacogenetics. 2004 ; 14: 595-605.
33. Hill G., Cihlar T., Oo C., et al. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos. 2002 ; 30: 13-19.
34. Marzolini C., Tirona RG, Kim RB Pharmacogenomics of the OATP and OAT families. Pharmacogenomics. 2004 ; 5: 273-282.
35. Fujita T., Brown C., Carlson EJ, et al. Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1). Pharmacogenet Genomics. 2005 ; 15: 201-209.
36. Bleasby K., Hall LA, Perry JL, Mohrenweiser HW, Pritchard JB Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6). J Pharmacol Exp Ther. 2005 ; 314: 923-931.
37. Kiso M., Mitamura K., Sakai-Tagawa Y., et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004 ; 364: 759-765.
38. Neuraminidase Inhibitor Susceptibility Network. Use of influenza antivirals during 2003-2004 and monitoring of neuraminidase inhibitor resistance. Wkly Epidemiol Rec. 2005 ; 80: 156.